Stock Analiz

Exagen Inc. XGN

Medical Specialities · IPO 2019 · data as of November 13, 2026

$4.13Market cap $105M
Open the interactive analysis →

Exagen Inc. (XGN) is a healthcare company listed in the US with a market value of about $105M. In the twelve months to September 30, 2026 it had revenue of $72M and net income of -$18M, a net margin of -25.1%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 10% a year, a 5-year average ROIC of -33%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.

About Exagen

Exagen is listed in the US and classified in medical specialities, IPO year 2019. Revenue went from $32M in 2018 to $67M in 2025, growth of about 10.8% a year. It was profitable in 0 of the last 8 years in our data. Its share count rose by 26% over three years (dilution for shareholders). It spends 9% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.5
P/B7.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-12.4%
Shareholder yield0.0%
Intrinsic value vs. price−97%

Growth and quality

Revenue growth (1 yr)19.7%
Revenue growth (5 yrs, per year)9.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-52.4%
ROIC (5-yr avg.)-32.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$72M$67M$56M$53M$46M$48M$42M$40M$32M
Net income-$18M-$20M-$15M-$24M-$47M-$27M-$17M-$12M-$8M
Free cash flow-$13M-$14M-$14M-$15M-$36M-$23M-$15M-$10M-$10M
EPS (diluted)$-0.75$-0.93$-0.83$-1.34$-2.77$-1.68$-1.32$-8.46$-293.34
Net margin-25.1%-30.0%-27.2%-45.1%-104.0%-55.6%-39.8%-29.8%-24.7%
ROIC—-26.5%-33.1%-39.3%-47.3%-16.9%-17.5%-9.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Exagen stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Exagen pay a dividend?

Not currently.

Is Exagen a good stock to buy?

We do not give buy or sell advice. Exagen scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.